Healthcare Industry News: Transdermal
News Release - February 1, 2006
Sontra Medical Serves Patent Infringement Notice for Dermisonics' Transdermal Insulin Delivery SystemFRANKLIN, Mass., Feb. 1 (HSMN NewsFeed) -- Sontra Medical Corporation (Nasdaq: SONT ) announced today that it has sent a notice to Dermisonics, Inc. (OTC Bulletin Board: DMSI.OB ) stating Sontra's belief that, upon commercialization, Dermisonics' U-Strip ultrasonic Transdermal delivery system for insulin and other drugs will infringe one or more of Sontra's patents. On February 1, 2006, Sontra sent a letter to Dermisonics stating that Sontra believes that the U-Strip system currently infringes, or will infringe, the claims in Sontra's U.S. patent numbers 6,002,961, 6,190,315, and/or 6,491,657, noting that the penalties for such infringement are severe, including a preliminary and permanent injunction, treble damages and attorneys' fees. Such letter follows several earlier letters and communications by Sontra to Dermisonics over the past several months regarding this matter. Sontra has offered to negotiate the terms of a mutually agreeable license agreement with Dermisonics, but has to date received no response.
Thomas W. Davison, Sontra's President and Chief Executive Officer, stated, "We are very concerned that Dermisonics is or very soon will be infringing on our patents with its U-Strip system for the Transdermal delivery of insulin and other drugs. As both companies share mutual interests in the areas of diabetes management and drug delivery, we have offered to license our technology to Dermisonics, but have not yet received from them any indication of a willingness to establish fair license terms. Sontra takes this matter very seriously and will take all necessary actions to protect our intellectual property and Dermisonics is on notice that the U-Strip system has serious patent infringement concerns."
About Sontra Medical Corporation (http://www.sontra.com)
Sontra Medical Corporation is a technology leader in Transdermal science. Sontra's SonoPrep ultrasound-mediated skin permeation technology combined with technical competencies in Transdermal drug formulation, delivery systems and biosensors is creating a new paradigm in Transdermal drug delivery and diagnosis. The SonoPrep technology is being developed for several billion dollar market opportunities, including continuous glucose monitoring and the Transdermal delivery of large molecule drugs and vaccines. Sontra is currently marketing the SonoPrep device and procedure tray for use with topical lidocaine to achieve rapid (within five minutes) skin anesthesia.
SonoPrep is a registered trademark of Sontra Medical Corporation. All other company, product or service names mentioned herein are the trademarks or registered trademarks of their respective owners.
This press release contains forward-looking statements, which address a variety of subjects including, for example, the expected benefits and efficacy of the SonoPrep device in connection with diagnostics, vaccine delivery, glucose monitoring and Transdermal drug delivery, Sontra's expected ability to develop, market and sell products based on its technology, the expected size of the markets for the SonoPrep device and technology, Sontra's ability to license its technology to Dermisonics, and Sontra's business, research, product development, regulatory approval, marketing and distribution plans and strategies. Statements that are not historical facts, including statements about our beliefs and expectations, are forward-looking statements. Such statements are based on our current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The following important factors and uncertainties, among others, could cause actual results to differ materially from those described in these forward- looking statements: our technology is new and we may experience adverse results in research collaborations, product development, clinical trials, product evaluations, commercialization efforts, product distribution and market acceptance; markets for our products may develop slower than expected, or not at all; our sales cycle is lengthy and we are still developing sales and marketing strategies which may or may not prove effective; the SonoPrep device may not prove effective in connection with diagnostics, vaccine delivery, glucose monitoring and/or Transdermal drug delivery; we may experience difficulties or delays in obtaining regulatory approvals to market products resulting from development efforts or difficulties or delays associated with sources of regulatory-approved Transdermal drugs and vaccines; failure to obtain and maintain patent protection for discoveries or commercial limitations imposed by patents owned or controlled by third parties would have an adverse effect on us; we depend upon strategic partners and third-party distributors to develop, commercialize, market and sell products based on our work; and we require substantial additional funding to conduct research and development and to expand commercialization, distribution and marketing activities. For detailed information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to Sontra's filings with the Securities and Exchange Commission, including Sontra's most recent Quarterly Report on Form 10-QSB. Forward-looking statements represent management's current expectations and are inherently uncertain. We do not undertake any obligation to update forward- looking statements made by us.
Source: Sontra Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.